Follow
Olivier RASCOL
Olivier RASCOL
UT3 Professor, CHU Purpan, Tonic (INSERM-UT3), CIC 1436 (INSERM-CHU-UT3), TMBI (Univ. Toulouse)
Verified email at univ-tlse3.fr
Title
Cited by
Cited by
Year
Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): scale presentation and clinimetric testing results
CG Goetz, BC Tilley, SR Shaftman, GT Stebbins, S Fahn, ...
Movement disorders: official journal of the Movement Disorder Society 23 (15 …, 2008
70152008
Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on …
CG Goetz, W Poewe, O Rascol, C Sampaio, GT Stebbins, C Counsell, ...
Movement disorders 19 (9), 1020-1028, 2004
27492004
A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
O Rascol, DJ Brooks, AD Korczyn, PP De Deyn, CE Clarke, AE Lang
New England Journal of Medicine 342 (20), 1484-1491, 2000
20292000
Association between early-onset Parkinson's disease and mutations in the parkin gene
CB Lücking, A Dürr, V Bonifati, J Vaughan, G De Michele, T Gasser, ...
New England Journal of Medicine 342 (21), 1560-1567, 2000
19382000
Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): process, format, and clinimetric testing plan
CG Goetz, S Fahn, P Martinez‐Martin, W Poewe, C Sampaio, GT Stebbins, ...
Movement disorders 22 (1), 41-47, 2007
16212007
The unified Parkinson's disease rating scale (UPDRS): status and recommendations
Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease
Movement Disorders 18 (7), 738-750, 2003
13772003
The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease
K Seppi, D Weintraub, M Coelho, S Perez‐Lloret, SH Fox, ...
Movement disorders 26 (S3), S42-S80, 2011
11502011
A double-blind, delayed-start trial of rasagiline in Parkinson's disease
CW Olanow, O Rascol, R Hauser, PD Feigin, J Jankovic, A Lang, ...
New England Journal of Medicine 361 (13), 1268-1278, 2009
10692009
Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL‐PET study
AL Whone, RL Watts, AJ Stoessl, M Davis, S Reske, C Nahmias, AE Lang, ...
Annals of neurology 54 (1), 93-101, 2003
10562003
The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease
SH Fox, R Katzenschlager, SY Lim, B Ravina, K Seppi, M Coelho, ...
Movement Disorders 26 (S3), S2-S41, 2011
8412011
Depression rating scales in Parkinson's disease: critique and recommendations
A Schrag, P Barone, RG Brown, AFG Leentjens, WM McDonald, ...
Movement disorders 22 (8), 1077-1092, 2007
8302007
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily …
O Rascol, DJ Brooks, E Melamed, W Oertel, W Poewe, F Stocchi, ...
The Lancet 365 (9463), 947-954, 2005
8002005
Cortical motor reorganization in akinetic patients with Parkinson's disease: a functional MRI study
U Sabatini, K Boulanouar, N Fabre, F Martin, C Carel, C Colonnese, ...
Brain 123 (2), 394-403, 2000
7452000
Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial
P Barone, W Poewe, S Albrecht, C Debieuvre, D Massey, O Rascol, ...
The Lancet Neurology 9 (6), 573-580, 2010
6812010
Development and validation of the unified multiple system atrophy rating scale (UMSARS)
GK Wenning, F Tison, K Seppi, C Sampaio, A Diem, F Yekhlef, I Ghorayeb, ...
Movement Disorders 19 (12), 1391-1402, 2004
6482004
The natural history of multiple system atrophy: a prospective European cohort study
GK Wenning, F Geser, F Krismer, K Seppi, S Duerr, S Boesch, ...
The lancet neurology 12 (3), 264-274, 2013
5842013
Summary of the recommendations of the EFNS/MDS‐ES review on therapeutic management of P arkinson's disease
JJ Ferreira, R Katzenschlager, BR Bloem, U Bonuccelli, D Burn, ...
European journal of neurology 20 (1), 5-15, 2013
5772013
Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial
S Palfi, JM Gurruchaga, GS Ralph, H Lepetit, S Lavisse, PC Buttery, ...
The Lancet 383 (9923), 1138-1146, 2014
5372014
Evidence‐based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004
CG Goetz, W Poewe, O Rascol, C Sampaio
Movement disorders: official journal of the Movement Disorder Society 20 (5 …, 2005
5362005
Priorities in Parkinson's disease research
WG Meissner, M Frasier, T Gasser, CG Goetz, A Lozano, P Piccini, ...
Nature reviews Drug discovery 10 (5), 377-393, 2011
5352011
The system can't perform the operation now. Try again later.
Articles 1–20